Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy Compared with Best Supportive Care for Metastatic/Unresectable Gallbladder Cancer: a Non-randomized Prospective Cohort Study

  • ORIGINAL ARTICLE
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Gallbladder cancer (GBC) is the most common biliary tract malignancy. Incidence varies widely with geographic regions, with northern India being the endemic area for GBC. Curative surgery offers the only chance of cure, but most of patients present with unresectable or metastatic disease and are candidates for palliative treatment only. This study was designed to evaluate efficacy of chemotherapy over best supportive care in unresectable/metastatic GBC. Patients with unresectable/metastatic GBC with proven tissue diagnosis were enrolled for single institution non-randomized prospective cohort study between May 2012 and April 2014. A total of 65 patients received palliative chemotherapy; either combination chemotherapy (n = 59) or single agent chemotherapy (n = 6). Combination chemotherapy regimen were either three weekly Gemcitabine-Cisplatin (n = 45) or Gemcitabine-Oxaliplatin (n = 14) for a maximum of six cycles. Twenty patients, either unfit for chemotherapy or unwilling for the same were advised best supportive care (BSC). The overall response rate to chemotherapy was 34 %. Median survival for chemotherapy group and BSC group were 35.6 and 13 weeks, respectively (p value < 0.001). Median OS for combination chemotherapy (n = 59) and single agent chemotherapy (n = 6) were 37 and 26.7 weeks, respectively (p value- 0.002). Median PFS for combination chemotherapy and single agent chemotherapy were 26 and 15 weeks, respectively (p value-0.012). The results of this study are quite encouraging and support use of chemotherapy for unresectable GBC patients over best supportive care, and that gemcitabine based combination chemotherapy may be a better choice for response rates, OS, and PFS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig 3

Similar content being viewed by others

References

  1. Randi G, Franceschi S, La VC (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591

    Article  CAS  PubMed  Google Scholar 

  2. Shukla VK, Roy SK, Vaidya MP (1985) Primary carcinoma gallbladder: a review of a 16 year period at the university hospital. J Surg Oncol 28:32–35

    Article  CAS  PubMed  Google Scholar 

  3. Perpetuo MO, Valdivieso M, Heilbrun LK et al (1978) Natural history study of gallbladder cancer: a review of 36 years experience at M.D. Anderson Cancer Center. Cancer 42:330–335

    Article  CAS  PubMed  Google Scholar 

  4. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306–10

    CAS  PubMed  Google Scholar 

  5. Harvey JH, Smith FP, Schein PS (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2:1245–8

    CAS  PubMed  Google Scholar 

  6. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med;362:1273–81

  8. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, Ahumada M (2001) A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12:1403–6

    Article  CAS  PubMed  Google Scholar 

  9. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, Awasthy BS (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90:1516–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28:4581–6

  11. Mekeel KL, Hemming AW (2007) Surgical management of gallbladder carcinoma: a review. J Gastrointest Surg 11:1188–93

    Article  PubMed  Google Scholar 

  12. Glimelius B, Hoffman K, Sjo¨de’n PO et al (1996) Chemotherapy improves survival and quality of life in pancreatic and biliary tract cancer. Ann Oncol 7:593–600

    Article  CAS  PubMed  Google Scholar 

  13. Takada T, Nimura Y, Katoh H et al (1998) Prospective randomized trial of 5 fluorouracil, doxorubicin, and mitomycin C for non resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 45:2020–2026

    CAS  PubMed  Google Scholar 

  14. Andre’ T, Tournigand C, Rosmorduc O, GERCOR Group et al (2004) Gemcitabine combined with Oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339–1343

    Article  Google Scholar 

  15. Cassier PA, Thevenet C, Walterb T et al (2010) Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. Eur J Gastroenterol Hepatol 22:1111–1117

    Article  CAS  PubMed  Google Scholar 

  16. Makela JT, Kairaluorna MI (1993) Superselective intra-arterial chemotherapy with mitomycin for gallbladder cancer. Br J Surg 159:415–20

    Google Scholar 

  17. Eckel F, Brunner T, Jelic S, Grp EGW (2011) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 22:vi40–vi44

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Army Hospital (Research & Referral), New Delhi-10, India

    Santosh Kumar Singh, Rajnish Talwar, Arvind Kumar Tyagi, Pradeep Jaiswal & Adarsh Kumar

  2. Command Hospital (SC), Pune, 411040, India

    Narayanan Kannan

Authors
  1. Santosh Kumar Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajnish Talwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narayanan Kannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arvind Kumar Tyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pradeep Jaiswal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Adarsh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Santosh Kumar Singh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S.K., Talwar, R., Kannan, N. et al. Chemotherapy Compared with Best Supportive Care for Metastatic/Unresectable Gallbladder Cancer: a Non-randomized Prospective Cohort Study. Indian J Surg Oncol 7, 25–31 (2016). https://doi.org/10.1007/s13193-015-0443-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-015-0443-7

Keywords

Search

Navigation